• No results found

University of Groningen Novel preclinical models, therapies and biomarkers for testicular cancer Rosas Plaza, Fernanda

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Novel preclinical models, therapies and biomarkers for testicular cancer Rosas Plaza, Fernanda"

Copied!
4
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Novel preclinical models, therapies and biomarkers for testicular cancer

Rosas Plaza, Fernanda

DOI:

10.33612/diss.119056452

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Rosas Plaza, F. (2020). Novel preclinical models, therapies and biomarkers for testicular cancer.

Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.119056452

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)
(3)

139

List of publications

1. Rosas Plaza X, van Agthoven T, Meijer C, van Vugt MATM, de Jong S,

Gietema JA, et al. miR-371a-3p, miR-373-3p and miR-367-3p as Serum

Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and

After Chemotherapy. Cells. 2019 Oct 8;8(10):1221.

2. Rosas-Plaza X, de Vries G, Meersma GJ, Suurmeijer AJH, Gietema JA, van Vugt

MAT., et al. Dual mTORC1/2 inhibition sensitizes testicular cancer models to

cisplatin treatment. Mol Cancer Ther. 2019 Nov 19; molcanther.0449.2019.

(4)

This research was financially supported by the Dutch Cancer

Society (grant numbers: EMCR13-6001 and RUG2014-6691)

Referenties

GERELATEERDE DOCUMENTEN

Recently, it was shown that hyperactivation of the PI3K/AKT/mTORC pathway was linked to cisplatin resistance in TC models where resistant sublines showed higher levels of p-AKT 473

In the present study, we therefore evaluated the possibility of using TC PDX models to study AFP and ß-HCG serum levels in relation to PDX growth and response to cisplatin

In Chapter 2, we investigated three microRNAs: miR-371a-3p, miR-373-3p and miR-367-3p as putative tumor biomarkers during and after treatment with cisplatin combination

Daarnaast hebben we onderzocht hoe humane testiskanker cellijnen en op humane testiskanker-gebaseerde diermodellen gevoelig kunnen worden gemaakt voor cisplatine.. Het doel van

Novel preclinical models, therapies and biomarkers for testicular cancer Rosas Plaza,

In Chapter 2, we investigated three microRNAs: miR-371a-3p, miR-373-3p and miR-367-3p as putative tumor biomarkers during and after treatment with cisplatin combination

Novel preclinical models, therapies and biomarkers for testicular cancer Rosas Plaza,

In a series of preclinical studies, we evaluated the utility of targeted liposomal delivery of DEX in models for prostate cancer bone metastases and showed enhanced antitumor